Please ensure Javascript is enabled for purposes of website accessibility
Search
Accessibility Menu
Intellia Therapeutics Stock Quote

Intellia Therapeutics (NASDAQ: NTLA)

$25.08
(-3.9%)
-$1.01
Price as of July 19, 2024, 4:00 p.m. ET

Intellia Therapeutics Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
NTLA -42.05% +46.67% +7.95% +13%
S&P +21.44% +86.27% +13.24% +168%

Intellia Therapeutics Company Info

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

News & Analysis

The Fool has written over 100 articles on Intellia Therapeutics.

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.